18F-Florbetaben PET/CT 检测心脏淀粉样变性与超声、心脏 MRI 及 DPD 显像的比较
该研究纳入 22 例确诊或临床怀疑心脏淀粉样变性的患者,评估 18F-Florbetaben PET/CT 的诊断性能,并与超声、心脏 MRI 及闪烁显像比较。PET 在 14/22 例中显示心肌摄取,8 例 PET 阴性者随后排除淀粉样变性;心肌示踪剂滞留与影像形态功能参数相关,且随访变化与治疗反应一致。
要点
- 18F-Florbetaben PET/CT 在 14/22 例中显示心肌摄取,8 例阴性者排除淀粉样变性。
- 不同淀粉样变性亚型显示特征性摄取模式(AL > AA > ATTR,均 p < 0.005)。
- 心肌示踪剂滞留与超声和心脏 MRI 参数相关,但与心脏生物标志物不相关。
核心结论
- 18F-Florbetaben PET/CT 检测心脏淀粉样变性可行,可能有助于区分淀粉样变性亚型。
研究设计与样本
- 纳入 22 例确诊(n=5)或临床怀疑(n=17)心脏淀粉样变性的患者行 18F-Florbetaben PET/CT 诊断性检查。
- 定性及定量评估包括计算心肌示踪剂滞留,并与超声(n=20)、心脏 MRI(n=16)、闪烁显像(n=16)及血清生物标志物比较。
- 4 例患者有随访 PET/CT(3 例开始治疗后,1 例监测)。
主要发现
- PET 显示 14/22 例心肌 18F-Florbetaben 滞留符合心脏淀粉样变性。
- 8 例 PET 阴性患者随后均排除心脏淀粉样变性怀疑。
- 淀粉样变性亚型显示特征性滞留模式(AL > AA > ATTR;均 p < 0.005)。
- 心肌示踪剂滞留与心脏 MRI 和超声测得的形态及功能参数相关(均 |r| > 0.47,均 p < 0.05),但与心脏生物标志物不相关。
- 心肌示踪剂滞留从基线至随访的变化与心脏生物标志物和体能状态评估的治疗反应一致。
临床怎么用
- 18F-Florbetaben PET/CT 可用于心脏淀粉样变性的诊断评估,PET 阴性有助于排除该病。
- 心肌示踪剂滞留定量可能用于区分淀粉样变性亚型及监测治疗反应。
局限性
- 样本量小(22 例),随访 PET/CT 仅 4 例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Cardiac amyloidosis (CA) is a rare cause of heart failure with frequently delayed diagnosis, because specific early signs or symptoms are missing. Recently, direct amyloid imaging using positron emission tomography/computed tomography (PET/CT) has emerged. The aim of this study was to examine the performance of 18F-florbetaben-PET/CT in detection of CA, and compare it to echocardiography (echo), cardiac MRI (CMR) and scintigraphy. Additionally, the use of 18F-florbetaben-PET/CT for quantification of amyloid burden and monitoring of treatment response was assessed. METHODS: Twenty-two patients with proven (n = 5) or clinical suspicion (n = 17) of CA underwent 18F-florbetaben-PET/CT for diagnostic work-up. Qualitative and quantitative assessment including calculation of myocardial tracer retention (MTR) was performed, and compared to echo (n = 20), CMR (n = 16), scintigraphy (n = 16) and serologic biomarkers (NT-proBNP, cTnT, free light chains). In four patients, follow-up PET/CT was available (after treatment initiation, n = 3; surveillance, n = 1). RESULTS: PET demonstrated myocardial 18F-florbetaben retention consistent with CA in 14/22 patients. Suspicion of CA was subsequently dropped in all eight PET-negative patients. Amyloid subtypes showed characteristic retention patterns (AL > AA > ATTR; all p < 0.005). MTR correlated with morphologic and functional parameters, as measured by CMR and echo (all r| > 0.47|, all p < 0.05), but not with cardiac biomarkers. Changes in MTR from baseline to follow-up corresponded well to treatment response, as assessed by cardiac biomarkers and performance status. CONCLUSIONS: Imaging of cardiac amyloidosis (CA) with 18F-florbetaben-PET/CT is feasible and might be useful in differentiating CA subtypes.
引用
- Kircher M, Ihne S, Brumberg J, et al. Detection of cardiac amyloidosis with 18F-Florbetaben-PET/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy. Eur J Nucl Med Mol Imaging. 2019. PMID: 30798427. doi:10.1007/s00259-019-04290-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。